<DOC>
	<DOCNO>NCT01077960</DOCNO>
	<brief_summary>In Serono Study 24380 , antecedent protocol Study 25373 , patient randomly assign 3.0-to-1.0 ratio Groups A B . All patient Group A receive recombinant human growth hormone ( Serostim® ) 4 mg daily ( `` induction '' phase ) first 12 week , re-randomized receive either placebo Serostim 2 mg alternate day ( roughly equivalent 1 mg daily ) Weeks 12-36 ( `` maintenance '' phase ) . All patient Group B initially receive placebo baseline Week 24 , receive Serostim® 4 mg daily Weeks 24 36 ( Grunfeld , 2007 ) . In follow-up Study 25373 , subject enrol Serono Study 24380 assign Group A , fully complete study visit without major protocol violation , eligible enroll receive re-treatment Serostim dose 4 mg daily 12 week . During study 25373 , safety monitor record adverse event measurement urinalysis laboratory blood test assess fast glucose , fast insulin , routine biochemistry hematology parameter . At Week 12 time study termination , subject underwent re-assessment body composition via anthropometry measurement dual photon absorptiometry ( DXA ) scan . In addition , study termination , measurement insulin-like growth factor I ( IGF-I ) , insulin-like growth bind protein 3 ( IGFBP-3 ) , fast lipid profile , oral glucose tolerance test obtain .</brief_summary>
	<brief_title>Safety Efficacy Study Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Must meet inclusion/exclusion criterion Serono Study 25373 , participate Serono Study 24380 , must assign Group A , must complete treatment procedure ( include baseline , Week 12 Week 36 Computerized Tomography ( CT ) DualEnergy Xray Absorptiometry ( DXA ) Scans ) major protocol violation . Must take antiretroviral medication approve available Treatment Investigational New Drug ( IND ) . Subjects must also agree discontinue change regimen duration study except judge medically necessary . Must willing able comply protocol duration study . Must voluntarily provide write informed consent subject authorization Health Insurance Portability Accountability Act 1996 ( HIPAA ) , prior studyrelated procedure part normal medical care , understand subject may withdraw consent time without prejudice future medical care . If female , subject must either : Be post menopausal ( =/ &gt; 1 year ) surgically sterilize ( i.e. , undergone tubal ligation hysterectomy ) , Use contraceptive method duration study : hormonal contraceptive , intra uterine device , diaphragm spermicide , condom spermicide , Must neither pregnant breast feeding . Confirmation female subject childbearing potential pregnant must establish negative pregnancy test prior initiate first treatment . A pregnancy test require subject post menopausal surgically sterilize . Have condition , interfere informed consent protocol compliance include , limited , active substance abuse and/or dementia . Have active malignancy , except localize cutaneous Kaposi 's sarcoma ( few 10 lesion , none large 2 cm , active therapy ) . Have active central nervous system ( CNS ) process associate neurological finding . Have acute illness treat intensive care unit , e.g. , due complication follow open heart abdominal surgery , multiple accidental trauma , acute respiratory failure . Have medical condition view study doctor and/or Serono Medical/Therapeutic Director feel would best interest subject participate followup study . Are unable comply Concomitant Therapy restriction outline Section 5.5 list follow : Therapy obesity include therapy anorexigenic fat reduce drug . Antidiabetic insulin sensitize medication . Systemic glucocorticoid . Systemic chemotherapy , interferon radiation therapy treatment . Androgenic agent include , limited , testosterone , nandrolone ( Decadurabolin ) , oxandrolone ( Oxandrin ) , oxymetholone ( Anadrol ) , dehydroepiandrosterone ( DHEA ) , etc . ( Testosterone replacement therapy hypogonadism exception exclusion allow start &gt; 30 day prior Study Day 1 Serono Study 24380 ) . Progestational agent , unless use oral contraception postmenopausal hormone replacement therapy . Appetite stimulant dronabinol ( Marinol ) , megestrol acetate ( Megace ) , cyproheptadine ( Periactin ) . Investigational agent , unless approve advance Serono 's Medical Director . Specifically , experimental antiretroviral agent disallow , unless available treatment IND expand access program ( 30 day ) . Liposuction elective plastic surgery . Acquired Immune Deficiency Syndrome ( AIDS ) waste therapy growth hormone and/or prior treatment growth hormone growth hormone release factor ( 12 month prior screen visit ) . Are participate clinical study ( except Serono Study 24380 ) . Observation study allow , prior write permission Serono Medical/Therapeutic Director must grant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Serostim</keyword>
	<keyword>HARS</keyword>
</DOC>